Hans Hagberg
Overview
Explore the profile of Hans Hagberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimby Professor Emerita E, Schar S, Pirosa M, Vanazzi A, Mey U, Rauch D, et al.
Blood Adv
. 2025 Jan;
PMID: 39883948
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus...
2.
Saren T, Ramachandran M, Gammelgard G, Lovgren T, Mirabello C, Bjorklund A, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4139-4152.
PMID: 37540566
Purpose: Although CD19 chimeric antigen receptor T cells (CAR-T) therapy has shown remarkable success in B-cell malignancies, a substantial fraction of patients do not obtain a long-term clinical response. This...
3.
4.
Hall K, Bruland O, Bjerkehagen B, Lidbrink E, Jebsen N, Hagberg H, et al.
Clin Sarcoma Res
. 2020 Dec;
10(1):22.
PMID: 33292545
Background: We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities...
5.
Kimby E, Lockmer S, Holte H, Hagberg H, Wahlin B, Brown P, et al.
Br J Haematol
. 2020 May;
191(5):738-747.
PMID: 32410260
Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while...
6.
Zucca E, Rondeau S, Vanazzi A, Ostenstad B, Mey U, Rauch D, et al.
Blood
. 2019 May;
134(4):353-362.
PMID: 31101627
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in...
7.
Lockmer S, Ostenstad B, Hagberg H, Holte H, Wahlin B, Wader K, et al.
J Clin Oncol
. 2019 Feb;
37(9):759-760.
PMID: 30735430
No abstract available.
8.
Lockmer S, Ostenstad B, Hagberg H, Holte H, Johansson A, Wahlin B, et al.
J Clin Oncol
. 2018 Oct;
:JCO1800262.
PMID: 30285560
Purpose: For indolent lymphoma, the optimal timing, sequence, and choice of therapeutic regimens remain a matter of debate. In two Nordic Lymphoma Group randomized trials, symptomatic or clearly progressing patients...
9.
Enblad G, Karlsson H, Gammelgard G, Wenthe J, Lovgren T, Amini R, et al.
Clin Cancer Res
. 2018 Aug;
24(24):6185-6194.
PMID: 30097433
Purpose: The chimeric antigen receptor (CAR) T-cell therapy has been effective for patients with CD19 B-cell malignancies. Most studies have investigated the second-generation CARs with either CD28 or 4-1BB costimulatory...
10.
Hall K, Bruland O, Bjerkehagen B, Zaikova O, Engellau J, Hagberg O, et al.
Eur J Cancer
. 2018 Jun;
99:78-85.
PMID: 29929092
Purpose: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously...